Organizations Filed Purposes:
Our work involves researching different potential medicines that may impact the onset of Alzheimers Disease. We work with pharmaceutical companies which are in various trial stages of developing these new drugs. Our job is to work with patients subjects who have early Alzheimer indications and want to try these trial drugs. Their participation in these studies helps us all understand ways to beat Alzheimers Disease.
Novartis: Generation 1 & 2 - Tests the safety and effects of the investgational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic status, and brain amyloid levels.
Biogen: Emerge Study - Evaluates the efficacy of the experimental drug aducanumab compared with a placebo in slowing cognitive and functional impairment in people with early-stage Alzheimer's disease.
Roche: Cread - This clinical trial tests the experimental drug crenezumab in people with early to mild Alzheimer's disease. It assesses the drug's safety and efficacy and evaluates any changes in particiapants' dementia rating and performanmce on neuropsychological tests.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Terry Hess | Foundation Mgr. | 40 | $135,082 |
| Maben Rainwater | Executive Dir. | 40 | $90,774 |
| Soraya Saffarinia | Secretary | 0 | $0 |
| Beth Bollinger | Chairman | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202020659349300712_public.xml